Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Shares Outstanding (Weighted Average): 2019-2024

Historic Shares Outstanding (Weighted Average) for Tonix Pharmaceuticals Holding (TNXP) over the last 6 years, with Dec 2024 value amounting to $1.9 million.

  • Tonix Pharmaceuticals Holding's Shares Outstanding (Weighted Average) rose 3883.74% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 3883.74%. This contributed to the annual value of $1.9 million for FY2024, which is 24976.37% up from last year.
  • Tonix Pharmaceuticals Holding's Shares Outstanding (Weighted Average) amounted to $1.9 million in FY2024, which was up 24,976.37% from $7,453 recorded in FY2023.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Shares Outstanding (Weighted Average) registered a high of $1.9 million during FY2024, and its lowest value of $245 during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $626,424, with a median of $7,453 in 2023.
  • Data for Tonix Pharmaceuticals Holding's Shares Outstanding (Weighted Average) shows a peak YoY soared of 24,976.37% (in 2024) over the last 5 years.
  • Tonix Pharmaceuticals Holding's Shares Outstanding (Weighted Average) (Yearly) stood at $245 in 2020, then soared by 180.41% to $687 in 2021, then surged by 318.78% to $2,877 in 2022, then skyrocketed by 159.05% to $7,453 in 2023, then soared by 24,976.37% to $1.9 million in 2024.